EMA approval for new drug to treat Alzheimer’s disease
A couple of weeks ago, the European Medicines Agency (EMA) gave the green light to the use of Lecanemab as a therapeutic option to try to slow the progression of a disease as prevalent and disabling as Alzheimer’s disease. [Weiterlesen]